Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KPTI logo KPTI
Upturn stock ratingUpturn stock rating
KPTI logo

Karyopharm Therapeutics Inc (KPTI)

Upturn stock ratingUpturn stock rating
$4.31
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KPTI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $29.25

1 Year Target Price $29.25

Analysts Price Target For last 52 week
$29.25Target price
Low$3.51
Current$4.31
high$16.95

Analysis of Past Performance

Type Stock
Historic Profit -48.57%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 38.38M USD
Price to earnings Ratio -
1Y Target Price 29.25
Price to earnings Ratio -
1Y Target Price 29.25
Volume (30-day avg) 6
Beta 0.23
52 Weeks Range 3.51 - 16.95
Updated Date 06/30/2025
52 Weeks Range 3.51 - 16.95
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.52

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -43.99%
Operating Margin (TTM) -110.8%

Management Effectiveness

Return on Assets (TTM) -44.76%
Return on Equity (TTM) -891.05%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 154699818
Price to Sales(TTM) 0.27
Enterprise Value 154699818
Price to Sales(TTM) 0.27
Enterprise Value to Revenue 1.09
Enterprise Value to EBITDA -1.85
Shares Outstanding 8639900
Shares Floating 7887109
Shares Outstanding 8639900
Shares Floating 7887109
Percent Insiders 6.39
Percent Institutions 42.62

Analyst Ratings

Rating 3
Target Price 29.25
Buy 3
Strong Buy 2
Buy 3
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Karyopharm Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Karyopharm Therapeutics Inc. was founded in 2008 and is a commercial-stage pharmaceutical company pioneering novel therapies for cancer and other diseases. It focuses on Selective Inhibitor of Nuclear Export (SINE) compounds.

business area logo Core Business Areas

  • Oncology: Focuses on the development and commercialization of therapies for hematologic malignancies and solid tumors.

leadership logo Leadership and Structure

Dr. Richard Paulson is the President and CEO. The company has a typical biotech structure with departments focused on research, development, commercialization, and administration.

Top Products and Market Share

overview logo Key Offerings

  • XPOVIO (selinexor): XPOVIO is an oral Selective Inhibitor of Nuclear Export (SINE) compound approved for multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Market share varies by indication and geography; specific figures are difficult to obtain due to competitive dynamics and limited public reporting. Competitors include Celgene/Bristol Myers Squibb, Amgen, Janssen, and Novartis, depending on the specific disease indication.

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and rapidly growing market driven by aging populations, increased cancer incidence, and advances in therapeutic options. The competitive landscape is intense with numerous pharmaceutical and biotechnology companies.

Positioning

Karyopharm is positioned as an innovative oncology company focused on developing novel SINE compounds. Its competitive advantage lies in its unique mechanism of action and its approved indications.

Total Addressable Market (TAM)

The global oncology market is expected to reach hundreds of billions of dollars. Karyopharm's XPOVIO is positioned to capture a segment of the MM and DLBCL markets, as well as potentially expand into other indications.

Upturn SWOT Analysis

Strengths

  • Approved product (XPOVIO)
  • Novel SINE technology platform
  • Experienced management team

Weaknesses

  • Reliance on a single product
  • High operating expenses
  • Limited commercial infrastructure

Opportunities

  • Expansion of XPOVIO into new indications
  • Partnerships and collaborations
  • Development of new SINE compounds

Threats

  • Competition from established therapies
  • Regulatory hurdles
  • Clinical trial failures
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • AMGN
  • JNJ
  • NVS

Competitive Landscape

Karyopharm faces stiff competition from larger pharmaceutical companies with established oncology portfolios. Karyopharm's advantage lies in its novel SINE technology, but it needs to successfully navigate the competitive landscape to achieve sustained growth. Note: Market share percentages are estimations.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the commercialization of XPOVIO. However, growth has been volatile due to market acceptance and competition.

Future Projections: Future growth is dependent on the successful expansion of XPOVIO into new indications and the development of new products.

Recent Initiatives: Recent initiatives include ongoing clinical trials, expansion of the commercial team, and partnerships.

Summary

Karyopharm is a developing company with an approved product and novel technology. It faces challenges related to competition, commercial execution, and financial stability. Expansion into new indications and strategic partnerships are crucial for future success. The company has a unique mechanism with XPOVIO which gives it a unique positioning.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Industry reports
  • Analyst estimates

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share estimations are based on available data and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Karyopharm Therapeutics Inc

Exchange NASDAQ
Headquaters Newton, MA, United States
IPO Launch date 2013-11-06
President, CEO & Director Mr. Richard A. Paulson M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 279
Full time employees 279

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.